Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
RAS mutation
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(21)
News
Trials
Search handles
@ArndtVogel
@DrHKantarjian
@DrVijayPatil11
@FordePatrick
@GillSharlene
@IbrahimSahinMD1
@SuyogCancer
@VivekSubbiah
@anup_kasi
@carlosbon78
@clacardone
@dr_yakupergun
@hemedoc
@jonathanloree
@jsoriamd
@malkadav
@mgfakih
@n_gangat
Search handles
@ArndtVogel
@DrHKantarjian
@DrVijayPatil11
@FordePatrick
@GillSharlene
@IbrahimSahinMD1
@SuyogCancer
@VivekSubbiah
@anup_kasi
@carlosbon78
@clacardone
@dr_yakupergun
@hemedoc
@jonathanloree
@jsoriamd
@malkadav
@mgfakih
@n_gangat
Filter by
Latest
9ms
Induction failure in T-acute lymphoblastic #leukemia. Persistent residual disease at EOC, and TAL1 lesions coupled with Myc and Ras mutations define patients with dismal prognosis @JCO_ASCO @drdavidoconnor https://t.co/GegUMRQpZt (@LohiOlli)
9 months ago
Clinical
|
RAS (Rat Sarcoma Virus)
|
RAS mutation
9ms
Brilliant lectures on RAS mutations, HER2 alterations and Claudin 18.2 overexpression in gastrointestinal cancers #WCGIC2023 (@carlosbon78)
9 months ago
HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18) • RAS (Rat Sarcoma Virus)
|
HER-2 overexpression • HER-2 mutation • RAS mutation • CLDN18.2 overexpression
9ms
#ASCO23 | N.Normanno presenta lo studio LIBImAb che indaga il ruolo delle mutazioni di RAS identificate tramite #biopsialiquida nella resistenza ai farmaci #antiEGFR. Qui il commento di Carmine Pinto ai risultati 👉🏼 https://t.co/9INfVax4ds @istitutotumori #colonretto #CRC (@Oncoinfo_it)
9 months ago
RAS (Rat Sarcoma Virus)
|
RAS mutation
10ms
👆 is a fascinating study, holding immense promise for future advancements. Along those remarkable lines, i have TESLA IIT that focuses on a groundbreaking vaccine specifically targets RAS mutant #PancreaticCancer in the post-adjuvant maintenance setting. https://t.co/GxYjjNgMnR (@anup_kasi)
10 months ago
Clinical
|
RAS (Rat Sarcoma Virus)
|
RAS mutation
10ms
Destiny -CRC02 Trastuzumab deruxtecan in CRC . For both k ras mutated and wild type . 5.4 mg per kg dose better tolerated Will it make it big in CRC ? @agrothey @GIcancerDoc @MPishvaian @asco @OncoAlert #ASCO23 (@SuyogCancer)
10 months ago
RAS (Rat Sarcoma Virus)
|
KRAS mutation • RAS mutation
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
10ms
Dr. Raghav presenting awaiting data from DESTINY CRC02 in HER2+ mCRC; different doses of trastuzumab deruxtecan explored, and pts with RAS wt/mutant tumors both included #ASCO2023 #ASCO23 @KristenCiombor (@OncLive)
10 months ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • RAS (Rat Sarcoma Virus)
|
RAS mutation • RAS wild-type
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
11ms
Impressive Talk from @MrinalPatnaik @MayoClinic RAS mutations drive pCMML, #CMML a RASopathy. And Ph1 trial w Onvasertib #MDS23 @MDSFoundation @aamdsif (@LugoMd)
11 months ago
RAS (Rat Sarcoma Virus)
|
RAS mutation
12ms
Read the #AACR23 abstract for the Phase I/II trial looking at combination of CXCR1/2 inhibitor with anti-PD-1 for ctDNA positive & refractory RAs-mutated microsatellite stable (MSS) colorectal cancer: https://t.co/5W8YV5BwoA @VanMorrisMD @adasarimd @skopetz @RonDePinho #EndCancer (@MDAndersonNews)
12 months ago
IO biomarker • Circulating tumor DNA
|
CXCR1 (Chemokine (C-X-C motif) receptor 1)
|
RAS mutation
12ms
Olaparib Plus Selumetinib Produces Clinical Benefit in RAS-Mutated Ovarian and Endometrial Cancer @ShannonWestin https://t.co/f6QAnUrqQW via @onclive (@VivekSubbiah)
12 months ago
Clinical
|
RAS (Rat Sarcoma Virus)
|
RAS mutation
|
Lynparza (olaparib) • Koselugo (selumetinib)
12ms
The recommended phase 2 dose of olaparib + selumetinib generated a clinical benefit in pts w/ endometrial or ovarian cancer harboring RAS mutations, according to the phase 1b SOLAR trial. @ShannonWestin @MDAndersonNews #ovca https://t.co/p0Uaj78rae (@OncLive)
12 months ago
Clinical
|
RAS (Rat Sarcoma Virus)
|
RAS mutation
|
Lynparza (olaparib) • Koselugo (selumetinib)
12ms
According to the phase 1b SOLAR trial, the recommended phase 2 dose of olaparib + selumetinib generated a clinical benefit in pts w/ endometrial or ovarian cancer harboring RAS mutations. @ShannonWestin @MDAndersonNews #ovca https://t.co/7YFvjRpGxR (@OncLive)
12 months ago
Clinical
|
RAS (Rat Sarcoma Virus)
|
RAS mutation
|
Lynparza (olaparib) • Koselugo (selumetinib)
12ms
A study led by our Dr. Shannon Westin shows Olaparib plus Selumetinib produces clinical benefit in RAS-mutated ovarian and endometrial cancer. Learn about her team's research here: https://t.co/avZ8aKkO8i @ShannonWestin @OncLive #Research #EndCancer (@MDAndersonNews)
12 months ago
Clinical
|
RAS (Rat Sarcoma Virus)
|
RAS mutation
|
Lynparza (olaparib) • Koselugo (selumetinib)
1year
Olaparib Plus Selumetinib Produces Clinical Benefit in RAS-Mutated Ovarian and Endometrial Cancer @ShannonWestin @MDAndersonNews @SGO_org #SGOMtg #gynsm #ovca https://t.co/w0YJRqukbk (@OncLive)
1 year ago
Clinical
|
RAS (Rat Sarcoma Virus)
|
RAS mutation
|
Lynparza (olaparib) • Koselugo (selumetinib)
1year
Exciting data from the SOLAR trial presented by @ShannonWestin on the use of combination PARPi and MEKi for RAS mutated recurrent ovarian and endometrial cancer! #SGOmtg #oncsurgery @MDAndersonNews (@aaronshafer99)
1 year ago
Surgery
|
RAS (Rat Sarcoma Virus)
|
RAS mutation
1year
Here's the wakelet link for those you missed last night's #CRCTrialsChat on #RAS mutated MSS Stage IV (metastatic) #ColorectalCancerAwarenessMonth Tagging @JonathanOstrem @jonathanloree @IbrahimSahinMD1 @PMBolandMD @MallaMidhun @NiuSanford @KrishanJethwa https://t.co/9b19CX8Mcl (@CrcTrialsChat)
1 year ago
Metastases
|
RAS (Rat Sarcoma Virus)
|
RAS mutation
1year
#CRCTrialsChat 💬 @manjuggm @jonathanloree @IbrahimSahinMD1 @KrishanJethwa 👏 👉v informative tweetorials on evolving understanding of RAS mutations in #CRCsm @OncoAlert (@GillSharlene)
1 year ago
RAS (Rat Sarcoma Virus)
|
RAS mutation
1year
The "Focus on #RAS mutated MSS St IV CRC" tweetchat begins in 10 min. Come join Drs @JonathanOstrem @jonathanloree @IbrahimSahinMD1 @MallaMidhun @PMBolandMD @NiuSanford @KrishanJethwa & @manjuggm in 10 min.. #CRCTrialsChat @OncoAlert #CRCSM (@CrcTrialsChat)
1 year ago
RAS (Rat Sarcoma Virus)
|
RAS mutation
1year
A 12-12 🇺🇸#NCI #KRAS adoptive cell trial phase I/II 📌https://t.co/eJMY7PtdcU 📌n=70 📌Peripheral🩸Leucocytes transduced with anti-KRAS G12D mTCR in HLA-A*11:01 (+) pts with St IV G12D mutant RAS solid tumors 📌Primary end points: Clinical response, safety #CRCTrialsChat (@manjuggm)
1 year ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase) • RAS (Rat Sarcoma Virus)
|
RAS mutation • KRAS G12
1year
A 12-13 🇺🇸#NCI #KRAS G12V adoptive cell trial phase I/II 📌https://t.co/f6PUwQVJao 📌n=110 📌Peripheral🩸Leukocytes transduced with anti-KRAS G12V mTCR in HLA-A*11:01 (+) pts with St IV G12V mutant RAS solid tumors 📌Primary end points: Clinical response, safety #CRCTrialsChat (@manjuggm)
1 year ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase) • RAS (Rat Sarcoma Virus)
|
KRAS G12V • RAS mutation • KRAS G12
1year
A 11. Things to keep in mind for patients 📌Test to know #RAS status 📌Know what SOC treatments are available 📌Use local treatments wherever possible 📌Look to trials early & include in treatment planning. 📌Don’t be restricted by the RAS mutation status #CRCTrialsChat #CRCSM (@manjuggm)
1 year ago
Clinical
|
RAS (Rat Sarcoma Virus)
|
RAS mutation
1year
A 9-2 Local treatment outcomes & RAS status 2022 https://t.co/Ho8dlAwxKH Substudy of RAXO Trial : N=906 Outcomes after metastasectomy for metastatic colorectal cancer (mCRC) vary with RAS and BRAF mutational status #CRCTrialsChat #CRCSM (@manjuggm)
1 year ago
Clinical • Metastases
|
BRAF (B-raf proto-oncogene) • RAS (Rat Sarcoma Virus)
|
BRAF mutation • RAS mutation
1year
A 7-1 📌Inside of a cancer, not all cells have the same mutation. 📌It’s unclear if it’s as bad if only part of a tumor has a RAS mutation as if most of the tumor has one. More on this next #CRCTrialsChat @OncoAlert #CRCSM (@jonathanloree)
1 year ago
RAS (Rat Sarcoma Virus)
|
RAS mutation
1year
A 7-5 📌 In RAS WT CRC patients, testing for RAS mutations at progression on tx with EGFRi is imp--these indicate resistant clones 📌With EGFRi re-challenge after the resistant clones have disappeared, EGFRi can work again! https://t.co/d5OzE0Jezz #CRCTrialsChat @OncoAlert (@jonathanloree)
1 year ago
Clinical
|
RAS (Rat Sarcoma Virus)
|
EGFR mutation • RAS mutation • RAS wild-type
1year
A3-5 📌RAS mutations are usually denoted by gene name (KRAS), codon affected (12) & amino acid change from the mutation, G (gylcine) to C (cysteine)- KRAS G12C 📌They can also be coded based on the nucleotide change (ie G12C = 34G>T). #CRCTrialsChat @OncoAlert #CRCSM (@jonathanloree)
1 year ago
KRAS (KRAS proto-oncogene GTPase) • RAS (Rat Sarcoma Virus)
|
KRAS mutation • KRAS G12C • RAS mutation • KRAS G12
1year
A 3-4 📌Among typical RAS mutations, KRAS G12C & G12D mutations have targeted therapy available in #clinicaltrials. 📌This is another reason why knowing your specific RAS mutation is important https://t.co/uiyosHMos8 #CRCTrialsChat #CRCSM #colorectalcancer (@jonathanloree)
1 year ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12D • RAS mutation • KRAS G12
1year
Welcome, Drs @PMBolandMD & @MallaMidhun, our new session mods for RAS mutated CRC! #CRCTrialsChat Let's 👀 at 📌What is RAS & its role in #CRC 📌Common CRC RAS muts & how to detect them 📌RAS🎯drug development 📌Tx of RAS mCRC & challenges 📌Trials for RAS mCRC See you soon! (@CrcTrialsChat)
1 year ago
RAS (Rat Sarcoma Virus)
|
RAS mutation
1year
So even with very low RAS mutant VAFs, still withhold EGFRi? @TumorBoardTues #CRCSM (@manjuggm)
1 year ago
RAS (Rat Sarcoma Virus)
|
EGFR mutation • RAS mutation
1year
15/22 #TumorBoardTuesday #ColonCancer ⏰When to rechallenge EGFR treatment? ⏰Optimal time to rechallenge with anti-EGFR mAb? Post-progression on anti-EGFR mAb, RAS & EGFR mutations decreases ⬇️ half life ≈ 4 months 📚 https://t.co/AoB8baoLIw (@RischZack)
1 year ago
RAS (Rat Sarcoma Virus)
|
RAS mutation
1year
Honourable Elena, Thank You for presentation at webinar just finished. I’ve just wrote the book about mutated K-ras cancers. Manuscript is based on the eight hundred articles mosaic. The model of carcinogenesis I’ve built showed some correlation among mK-RAS and TIMP3. (@UrbaKest)
1 year ago
KRAS (KRAS proto-oncogene GTPase) • RAS (Rat Sarcoma Virus) • TIMP3 (TIMP Metallopeptidase Inhibitor 3)
|
KRAS mutation • RAS mutation
1year
Possibly K-ras mutations appear in AML cells (12-27%) later and EGFR inhibition can’T help (@UrbaKest)
1 year ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • EGFR mutation • RAS mutation
1year
Proud to share the final results of #STREAM, an #academicstudy 🗣️#Regorafenib as 2-line treatment of patients with #RAS mutant advanced #CRCSM @ESMO_Open @AlfredoBudillon @alfdestefano @istitutotumori 👇 https://t.co/gChJV01XVy (@clacardone)
1 year ago
Clinical • Metastases
|
RAS (Rat Sarcoma Virus)
|
RAS mutation
|
Stivarga (regorafenib)
1year
Sotorasib in K-RAS mutated pancreatic cancer. Seems to have promise. But needs validation in a randomised study. I hope it doesn't nsclc way. @VanitaNoronha @Bhosale26Bharat @HHKhar https://t.co/CJHQdy99IX (@DrVijayPatil11)
1 year ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase) • RAS (Rat Sarcoma Virus)
|
KRAS mutation • RAS mutation
|
Lumakras (sotorasib)
over1year
The RAS mutation has been seen as an insurmountable target for 40 years. It has finally become targetable. We are just at the beginning of the road. We have a long road ahead of us, but the results are promising. Efficacy of sotorasib in pancreatic cancer👇 (@dr_yakupergun)
over 1 year ago
Clinical
|
RAS (Rat Sarcoma Virus)
|
RAS mutation
|
Lumakras (sotorasib)
over1year
A ways to go in R/R AML with P53/RAS/ASXL1 mutations.. #leusm #venetoclax #azacitidine #decitabine (@n_gangat)
over 1 year ago
ASXL1 (ASXL Transcriptional Regulator 1) • RAS (Rat Sarcoma Virus)
|
RAS mutation • ASXL1 mutation
|
Venclexta (venetoclax) • azacitidine • decitabine
over1year
#ASH22 #leusm Hyak: c-Kit mutations assoc w decreased DFS (and possibly OS) in CBF AML if VAF >10% but not if <10%. FLT3 and Ras mutations had no impact on survival outcomes. (@hemedoc)
over 1 year ago
FLT3 (Fms-related tyrosine kinase 3) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • RAS (Rat Sarcoma Virus)
|
KIT mutation • RAS mutation
over1year
The complex genomic landscape of #RAS-mutant tumors is described in this paper. Co-mutations with RAS are cancer lineage–specific & context-dependent manner. Enrichment in KRAS G12C mutations is seen in white females with NSCLC & colorectal carcinoma. https://t.co/D6nC35i1mD (@jsoriamd)
over 1 year ago
KRAS (KRAS proto-oncogene GTPase) • RAS (Rat Sarcoma Virus)
|
KRAS mutation • KRAS G12C • RAS mutation • KRAS G12
over1year
Proliferative CMML that is R/R or intolerant to HMA and/or Hydrea. While we don’t have mutational restrictions for enrollment we anticipate responses in #RAS pathway mutant #CMML #NRAS #KRAS #CBL #PTPN11 #NF1 (@MrinalPatnaik)
over 1 year ago
KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • NF1 (Neurofibromin 1) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11)
|
KRAS mutation • NRAS mutation • RAS mutation
|
hydroxyurea
over1year
An area of unmet need; K-ras mutant subtypes in colorectal cancer & lung cancer as well #Drug_Development #kras #PrecisionMedicine therapies @VivekSubbiah (@NaglaAKarimMD)
over 1 year ago
KRAS (KRAS proto-oncogene GTPase) • RAS (Rat Sarcoma Virus)
|
KRAS mutation • RAS mutation
over1year
New diagnosis #AML and RAS mutation = favorable outcome with araC regimens, and with hypomethylating agents + venetoclax | Tapan Kadia @TapKadia and Kantarjian of @MDAndersonNews #Leukemia https://t.co/ru5AcQ4aEv via @AjHematology #leusm (@DrHKantarjian)
over 1 year ago
RAS (Rat Sarcoma Virus)
|
RAS mutation
|
Venclexta (venetoclax)
over1year
The PLK1 Inhibitor Onvansertib Overcomes Irinotecan Resistance in RAS-mutated (mRAS) Metastatic Colorectal Cancer (mCRC) In Vivo and in Patients @skopetz @MDAndersonNews #ESMO22 @KRASKickers https://t.co/1EFGdn8e02 (@fireflyann)
over 1 year ago
KRAS (KRAS proto-oncogene GTPase) • PLK1 (Polo Like Kinase 1)
|
RAS mutation
|
irinotecan • onvansertib (PCM-075)
over1year
✳️Some important points: biomarker before starting therapy ! RAS/RAF mutations and perhaps also PIK3CA which may render resistance to HER2 therapy ❗️ ✳️Similar to antiEGFR therapy, patients with left sided colon cancer seems to benefit more from HER2 therapy over right sided❗️ (@IbrahimSahinMD1)
over 1 year ago
Clinical
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
|
PIK3CA mutation • RAS mutation
over1year
Targeting #RAS Mutant #ColorectalCancer with Dual Inhibition of MEK and CDK4/6, by Sorokin et al. https://t.co/iMkJfI1BX0 @VanMorrisMD @MDAndersonNews (@CR_AACR)
over 1 year ago
CDK4 (Cyclin-dependent kinase 4)
|
RAS mutation
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login